From $3M to $1.9B: GlaxoSmithKline inserts discarded Gilead drug into late-stage portfolio, buying out the turnaround crew at Sierra

Amber Tong

As a drug formerly abandoned by Gilead finally looks set to complete its tortuous journey toward FDA approval, GlaxoSmithKline is shelling out $1.9 billion to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

From $3M to $1.9B: GlaxoSmithKline inserts discarded Gilead drug into late-stage portfolio, buying out the turnaround crew at Sierra

Amber Tong

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

From $3M to $1.9B: Glax­o­SmithK­line in­serts dis­card­ed Gilead drug in­to late-stage port­fo­lio, buy­ing out the turn­around crew at Sier­ra

Amber Tong

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

From $3M to $1.9B: GlaxoSmithKline inserts discarded Gilead drug into late-stage portfolio, buying out the turnaround crew at Sierra

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Soleno’s rare pediatric disease drug faces PDUFA delay by three months